viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals says Clevegen partnership discussions continue

An update was provided in Faron’s 2019 results statement

Faron Pharmaceuticals Ltd -

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) said that negotiations with potential partners for its lead immunotherapy were continuing as it reported its full-year 2019 results.

The aim is to support the development of cancer treatment Clevegen, which is expected to be used in harness with other drugs.

Faron’s 2019 results statement covered a busy year for the Finnish drug developer and its lead drug:

  • The first part of the company’s phase I/II MATINS trial has begun in Europe
  • Clevegen has promoted a process called immune activation in all dosed patients
  • Partial responses to the treatment were observed in two treatments
  • Early data has shown Clevegen’s “early efficacy” and “good tolerability”
  • Sign-off to begin an early-stage trial in the US

Development of the company’s second drug Traumakine, for acute respiratory distress, is expected to be funded by an outside party.

After discussions with the US Food & Drug Administration the Traumakine phase III clinical trial design has been amended to ensure that there is no overlapping use of corticosteroids, which appear to impair the efficacy of the company’s interferon-beta drug.

Turning to the financials, Faron lost €13.3mln in 2019, a busy year for research and development. It closed out the period with €7.1mln of cash.

Quick facts: Faron Pharmaceuticals Ltd

Price: 479.9999 GBX

Market: AIM
Market Cap: £207.8 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...



Morning Report: FTSE 100 collapses as oil price war erupts

Headlines from the Proactive UK newsroom. Oil prices slumped by 30% on Monday as Saudi Arabia chopped prices after attempts to agree a production deal with Russia collapsed over the weekend. Brent crude plunged to US$31 a barrel after registering its largest daily drop since the Gulf...

3 weeks ago

2 min read